Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06434350 · ClinicalTrials.gov registry record · Phase 1
Enfortumab Vedotin With Radiation for Locally Advanced Bladder Cancer (CONSOLIDATE)
A Phase 1 study of Advanced Bladder Cancer, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 41
- Enrollment target
- 1
- Study location
NCT06434350 is a Phase 1 study of Advanced Bladder Cancer that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 41 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06434350, a Phase 1 study of Advanced Bladder Cancer, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 41 participants
- Enrollment target
- 1
- Study location
Study Summary
To learn if the combination of enfortumab vedotin plus radiation therapy could help to control the disease.
Conditions Studied
Interventions
- DRUG Enfortumab Vedotin
- RADIATION Radiation Therapy
Study Locations (1)
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2024-10-10 |
| Est. Completion | 2027-09-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06434350
The ClinicalTrials.gov registry entry for NCT06434350 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced Bladder Cancer appearing as the primary indexed condition, and to 2 interventions - of which Enfortumab Vedotin is the first listed.
NCT06434350 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT06434350 about?
NCT06434350 is a clinical study titled "Enfortumab Vedotin With Radiation for Locally Advanced Bladder Cancer (CONSOLIDATE)". To learn if the combination of enfortumab vedotin plus radiation therapy could help to control the disease.
What is the current status of trial NCT06434350?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 41 participants. The study started on 2024-10-10. Estimated completion is 2027-09-24.
What conditions does trial NCT06434350 study?
This clinical trial studies the following conditions: Advanced Bladder Cancer.
What interventions are being tested in trial NCT06434350?
The interventions under investigation include: Enfortumab Vedotin (DRUG), Radiation Therapy (RADIATION).
Who is sponsoring clinical trial NCT06434350?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06434350 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.